Related Experiment Video

Updated: May 19, 2026

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery
09:09

Synthesis of Aptamer-PEI-g-PEG Modified Gold Nanoparticles Loaded with Doxorubicin for Targeted Drug Delivery

Published on: June 23, 2020

Mesoporous Silica Nanoparticles With Customized Drug Ratio/Loading for Effective Treatment of Gemcitabine-Resistant

Tamanna Binte Huq1,2, Sudip Kumar Dam1,2, Doaha Awad3

  • 1Department of Chemistry, University of North Carolina at Charlotte, Charlotte, North Carolina, USA.

Advanced Nanobiomed Research
|May 18, 2026
PubMed

Insights

New mesoporous silica nanoparticles deliver chemotherapy drugs Gemcitabine and Cisplatin effectively, even in Gemcitabine-resistant pancreatic cancer models. This novel drug delivery system shows promise for treating refractory pancreatic ductal adenocarcinoma.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Pancreatic ductal adenocarcinoma (PDAC) has poor prognosis due to metastasis and chemoresistance.
  • Gemcitabine (Gem) efficacy is limited by poor uptake and resistance.
  • Novel drug delivery is needed for treatment-refractory PDAC.

Purpose of the Study:

  • Develop redox-responsive mesoporous silica nanoparticles (MSNs) for Gemcitabine (Gem) and Cisplatin (cisPt) delivery.
  • Evaluate MSN-based mono- and codelivery in Gem-resistant (GR) PDAC models.
  • Optimize Gem and cisPt loading and ratios within MSNs.

Main Methods:

  • Formulated Gem-MSNs and Gem-cisPt-MSNs with varying drug loads.
  • Established Gem-resistant murine (GR-KCM) and human (GR-BxPC3) PDAC cell models.
  • Assessed cytotoxicity, cell cycle arrest, apoptosis, and reactive oxygen species (ROS) in vitro.

Main Results:

  • Gem-MSNs (10%wt) and Gem-cisPt-MSN (10:9%wt) showed significant cytotoxicity in GR PDAC models.
  • Gem-cisPt-MSN (18:9%wt) induced S-phase arrest, apoptosis, and increased ROS.
  • Optimized MSN formulations enhanced therapeutic effects against resistant PDAC.

Conclusions:

  • MSN-based delivery systems can overcome Gemcitabine resistance in PDAC.
  • Codelivery of Gem and cisPt via MSNs offers a promising strategy for refractory PDAC.
  • This approach enhances chemotherapy efficacy in treatment-resistant pancreatic cancer.
Keywords:
combination therapycontrolled releasegemcitabine resistancemesoporous silica nanoparticlespancreatic cancer

More Related Videos

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice08:57

Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice

Published on: October 5, 2017

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.